Cargando…

Comparison between theophylline, N-acetylcysteine, and theophylline plus N-acetylcysteine for the prevention of contrast-induced nephropathy

BACKGROUND: Few studies compared the efficacy of theophylline with N-acetylcysteine or evaluated the efficacy of combination therapy in the prevention of contrast-induced nephropathy (CIN). We compared the efficacy of theophylline, N-acetylcysteine, and the combination of these agents in the prevent...

Descripción completa

Detalles Bibliográficos
Autores principales: Arabmomeni, Morteza, Najafian, Jamshid, Abdar Esfahani, Morteza, Samadi, Mohsen, Mirbagher, Leila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Isfahan Cardiovascular Research Center, Isfahan University of Medical Sciences 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4460352/
https://www.ncbi.nlm.nih.gov/pubmed/26089930
_version_ 1782375378663243776
author Arabmomeni, Morteza
Najafian, Jamshid
Abdar Esfahani, Morteza
Samadi, Mohsen
Mirbagher, Leila
author_facet Arabmomeni, Morteza
Najafian, Jamshid
Abdar Esfahani, Morteza
Samadi, Mohsen
Mirbagher, Leila
author_sort Arabmomeni, Morteza
collection PubMed
description BACKGROUND: Few studies compared the efficacy of theophylline with N-acetylcysteine or evaluated the efficacy of combination therapy in the prevention of contrast-induced nephropathy (CIN). We compared the efficacy of theophylline, N-acetylcysteine, and the combination of these agents in the prevention of CIN. METHODS: This randomized controlled trial was conducted on 96 patients referring consecutively to the Shahid Chamran University Hospital in Isfahan, Iran, for elective coronary angiography (with our without angioplasty). Patients with at least moderate risk for CIN were included and were randomized to receive theophylline (200 mg), N-acetylcysteine (600 mg), or theophylline + N-acetylcysteine, twice a day, from 24 h before to 48 h after administration of the contrast material. A non-ionic, low-osmolar contrast material was used. Serum creatinine was measured before and 48 h after contrast material injection. RESULTS: Serum creatinine was increased by 6.83 ± 15.32% with theophylline, 13.09 ± 14.63% with N-acetylcysteine, and 5.45 ±1 3.96% with theophylline + N-acetylcysteine after contrast material injection (between group P = 0.072). Controlling for Mehran risk score, baseline serum creatinine, and contrast volume, the change in serum creatinine level was lower with theophylline compared with N-acetylcysteine (F = 4.79, P = 0.033), and with theophylline + N-acetylcysteine compared with N-acetylcysteine (F = 5.78, P = 0.020). CIN (increase in creatinine of ≥ 0.5 mg/dl or ≥ 25% from the baseline) was occurred in 20%, 21.9%, and 7.1% of patients in the theophylline, N-acetylcysteine, and theophylline + N-acetylcysteine groups, respectively (P = 0.260). CONCLUSION: Theophylline is superior to N-acetylcysteine in preventing contrast-induced renal dysfunction, but the combination with N-acetylcysteine is not superior to theophylline alone in this regard. Further trials with larger sample of patients are warranted.
format Online
Article
Text
id pubmed-4460352
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Isfahan Cardiovascular Research Center, Isfahan University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-44603522015-06-18 Comparison between theophylline, N-acetylcysteine, and theophylline plus N-acetylcysteine for the prevention of contrast-induced nephropathy Arabmomeni, Morteza Najafian, Jamshid Abdar Esfahani, Morteza Samadi, Mohsen Mirbagher, Leila ARYA Atheroscler Original Article BACKGROUND: Few studies compared the efficacy of theophylline with N-acetylcysteine or evaluated the efficacy of combination therapy in the prevention of contrast-induced nephropathy (CIN). We compared the efficacy of theophylline, N-acetylcysteine, and the combination of these agents in the prevention of CIN. METHODS: This randomized controlled trial was conducted on 96 patients referring consecutively to the Shahid Chamran University Hospital in Isfahan, Iran, for elective coronary angiography (with our without angioplasty). Patients with at least moderate risk for CIN were included and were randomized to receive theophylline (200 mg), N-acetylcysteine (600 mg), or theophylline + N-acetylcysteine, twice a day, from 24 h before to 48 h after administration of the contrast material. A non-ionic, low-osmolar contrast material was used. Serum creatinine was measured before and 48 h after contrast material injection. RESULTS: Serum creatinine was increased by 6.83 ± 15.32% with theophylline, 13.09 ± 14.63% with N-acetylcysteine, and 5.45 ±1 3.96% with theophylline + N-acetylcysteine after contrast material injection (between group P = 0.072). Controlling for Mehran risk score, baseline serum creatinine, and contrast volume, the change in serum creatinine level was lower with theophylline compared with N-acetylcysteine (F = 4.79, P = 0.033), and with theophylline + N-acetylcysteine compared with N-acetylcysteine (F = 5.78, P = 0.020). CIN (increase in creatinine of ≥ 0.5 mg/dl or ≥ 25% from the baseline) was occurred in 20%, 21.9%, and 7.1% of patients in the theophylline, N-acetylcysteine, and theophylline + N-acetylcysteine groups, respectively (P = 0.260). CONCLUSION: Theophylline is superior to N-acetylcysteine in preventing contrast-induced renal dysfunction, but the combination with N-acetylcysteine is not superior to theophylline alone in this regard. Further trials with larger sample of patients are warranted. Isfahan Cardiovascular Research Center, Isfahan University of Medical Sciences 2015-01 /pmc/articles/PMC4460352/ /pubmed/26089930 Text en © 2014 Isfahan Cardiovascular Research Center & Isfahan University of Medical Sciences http://creativecommons.org/licenses/by-nc/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
spellingShingle Original Article
Arabmomeni, Morteza
Najafian, Jamshid
Abdar Esfahani, Morteza
Samadi, Mohsen
Mirbagher, Leila
Comparison between theophylline, N-acetylcysteine, and theophylline plus N-acetylcysteine for the prevention of contrast-induced nephropathy
title Comparison between theophylline, N-acetylcysteine, and theophylline plus N-acetylcysteine for the prevention of contrast-induced nephropathy
title_full Comparison between theophylline, N-acetylcysteine, and theophylline plus N-acetylcysteine for the prevention of contrast-induced nephropathy
title_fullStr Comparison between theophylline, N-acetylcysteine, and theophylline plus N-acetylcysteine for the prevention of contrast-induced nephropathy
title_full_unstemmed Comparison between theophylline, N-acetylcysteine, and theophylline plus N-acetylcysteine for the prevention of contrast-induced nephropathy
title_short Comparison between theophylline, N-acetylcysteine, and theophylline plus N-acetylcysteine for the prevention of contrast-induced nephropathy
title_sort comparison between theophylline, n-acetylcysteine, and theophylline plus n-acetylcysteine for the prevention of contrast-induced nephropathy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4460352/
https://www.ncbi.nlm.nih.gov/pubmed/26089930
work_keys_str_mv AT arabmomenimorteza comparisonbetweentheophyllinenacetylcysteineandtheophyllineplusnacetylcysteineforthepreventionofcontrastinducednephropathy
AT najafianjamshid comparisonbetweentheophyllinenacetylcysteineandtheophyllineplusnacetylcysteineforthepreventionofcontrastinducednephropathy
AT abdaresfahanimorteza comparisonbetweentheophyllinenacetylcysteineandtheophyllineplusnacetylcysteineforthepreventionofcontrastinducednephropathy
AT samadimohsen comparisonbetweentheophyllinenacetylcysteineandtheophyllineplusnacetylcysteineforthepreventionofcontrastinducednephropathy
AT mirbagherleila comparisonbetweentheophyllinenacetylcysteineandtheophyllineplusnacetylcysteineforthepreventionofcontrastinducednephropathy